MX341426B - Metodos para preparar composiciones en polvo seco de glicopirrolato. - Google Patents

Metodos para preparar composiciones en polvo seco de glicopirrolato.

Info

Publication number
MX341426B
MX341426B MX2012008068A MX2012008068A MX341426B MX 341426 B MX341426 B MX 341426B MX 2012008068 A MX2012008068 A MX 2012008068A MX 2012008068 A MX2012008068 A MX 2012008068A MX 341426 B MX341426 B MX 341426B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
relates
present
producing
over time
Prior art date
Application number
MX2012008068A
Other languages
English (en)
Inventor
Morton David
Shott Martin
Davies Rebecca
Original Assignee
Vectura Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341426(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd * filed Critical Vectura Ltd *
Publication of MX341426B publication Critical patent/MX341426B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención concierne a composiciones farmacéuticas que comprenden el agente anti-muscarínico glicopirrolato, por ejemplo la sal bromuro de glicopirrolato. En particular, la presente invención concierne a composiciones en polvo eco que exhiben estabilidad mejorada durante el tiempo, y a métodos para producirlas.
MX2012008068A 2004-04-30 2006-10-27 Metodos para preparar composiciones en polvo seco de glicopirrolato. MX341426B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX341426B true MX341426B (es) 2016-08-18

Family

ID=32408337

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA06012493A MXPA06012493A (es) 2004-04-30 2005-04-29 Composiciones farmaceuticas.
MX2012008068A MX341426B (es) 2004-04-30 2006-10-27 Metodos para preparar composiciones en polvo seco de glicopirrolato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA06012493A MXPA06012493A (es) 2004-04-30 2005-04-29 Composiciones farmaceuticas.

Country Status (26)

Country Link
US (1) US20080063719A1 (es)
EP (3) EP2422766B1 (es)
JP (2) JP5000483B2 (es)
KR (1) KR101287919B1 (es)
CN (3) CN102008453A (es)
AU (2) AU2005237266B2 (es)
BR (1) BRPI0510500B8 (es)
CA (1) CA2563760C (es)
CY (6) CY1113069T1 (es)
DK (2) DK1755555T3 (es)
ES (2) ES2388289T3 (es)
GB (1) GB0409703D0 (es)
HU (4) HUE025463T2 (es)
IL (2) IL178651A (es)
LT (1) LTC2422766I2 (es)
LU (2) LU92176I2 (es)
MX (2) MXPA06012493A (es)
NO (1) NO20065502L (es)
NZ (1) NZ550479A (es)
PL (2) PL1755555T3 (es)
PT (2) PT2422766E (es)
RU (1) RU2396943C2 (es)
SG (3) SG152292A1 (es)
SI (2) SI2422766T1 (es)
WO (1) WO2005105043A2 (es)
ZA (1) ZA200609350B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
ES2460576T3 (es) * 2007-12-13 2014-05-13 Novartis Ag Procedimiento para preparar una sustancia farmacológica en partículas y cristalina
JP2011506399A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
PL3578169T3 (pl) 2009-02-26 2024-09-02 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
CN102458372A (zh) * 2009-04-24 2012-05-16 先灵公司 适用在干粉吸入器中的聚结物制剂
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
WO2011121425A1 (en) * 2010-03-31 2011-10-06 Glenmark Pharmaceuticals Limited Pharmaceutical powder composition for inhalation
BR112012024059B1 (pt) 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
DK2560611T3 (en) * 2010-04-21 2018-02-26 Chiesi Farm Spa Process for providing particles with reduced electrostatic charges
AU2011298409B2 (en) 2010-08-31 2013-11-21 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
AU2011298315B2 (en) 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
KR20150119468A (ko) 2013-02-28 2015-10-23 더미라, 인코포레이티드 글리코피롤레이트 염
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
SG11201700536XA (en) * 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
AU2015331915A1 (en) * 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder formulation
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
AU2016397046B2 (en) 2016-03-08 2022-05-12 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
MX385717B (es) 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
PL3490533T3 (pl) 2016-07-29 2020-11-02 Inke, S.A. Sposób stabilizacji rozmiaru cząstek
US10888546B2 (en) 2016-09-19 2021-01-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
HUE055425T2 (hu) 2017-12-11 2021-11-29 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus elzáródásos tüdõbetegség akut fokozódásának kezelésében
PT3585383T (pt) 2017-12-11 2021-04-21 Mereo Biopharma 1 Ltd Utilização de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida na prevenção ou redução de exacerbações graves da doença pulmonar obstrutiva crónica
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
US20250050042A1 (en) 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
CA2347856C (en) * 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
IL153705A0 (en) 2000-06-27 2003-07-06 Vectura Ltd Method of making particles for use in a pharmaceutical composition
JP4380988B2 (ja) * 2000-11-30 2009-12-09 ヴェクトゥラ リミテッド 医薬組成物に用いられる粒子の製造方法
ES2587135T3 (es) * 2000-11-30 2016-10-20 Vectura Limited Procedimiento de fabricación de partículas para su uso en una composición farmacéutica
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
JP2005530765A (ja) * 2002-05-07 2005-10-13 ネクター セラピューティクス 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
US20080063719A1 (en) 2008-03-13
IL178651A0 (en) 2007-02-11
IL178651A (en) 2012-12-31
CY2013012I1 (el) 2015-08-05
HUS1500073I1 (hu) 2016-02-29
AU2011200543B2 (en) 2012-11-29
CN102008453A (zh) 2011-04-13
CN1964700A (zh) 2007-05-16
EP2422767A3 (en) 2012-04-25
HK1095282A1 (en) 2007-05-04
SI1755555T1 (sl) 2012-10-30
JP5000483B2 (ja) 2012-08-15
EP2422766A3 (en) 2012-04-25
ZA200609350B (en) 2008-04-30
CY1113069T1 (el) 2015-08-05
CY2015060I1 (el) 2020-05-29
CY1116655T1 (el) 2017-03-15
HUS1500072I1 (hu) 2016-02-29
PT1755555E (pt) 2012-08-17
CY2014015I2 (el) 2015-12-09
MXPA06012493A (es) 2007-01-29
SG10201605001SA (en) 2016-08-30
RU2396943C2 (ru) 2010-08-20
EP2422766B1 (en) 2015-06-24
NZ550479A (en) 2009-11-27
LU92392I2 (fr) 2015-11-02
ES2388289T3 (es) 2012-10-11
LU92176I9 (es) 2019-01-04
PT2422766E (pt) 2015-10-12
ES2546982T3 (es) 2015-09-30
EP2422767A2 (en) 2012-02-29
SI2422766T1 (sl) 2015-10-30
WO2005105043A3 (en) 2006-05-04
KR101287919B1 (ko) 2013-07-18
DK2422766T3 (da) 2015-08-31
AU2011200543A8 (en) 2011-03-31
CY2013012I2 (el) 2015-08-05
HUE025463T2 (en) 2016-02-29
AU2005237266A1 (en) 2005-11-10
BRPI0510500B1 (pt) 2019-04-24
JP2012031209A (ja) 2012-02-16
IL223545A0 (en) 2013-02-03
WO2005105043A2 (en) 2005-11-10
SG152292A1 (en) 2009-05-29
EP1755555A2 (en) 2007-02-28
CN107252423A (zh) 2017-10-17
KR20070033978A (ko) 2007-03-27
CY2014015I1 (el) 2015-12-09
JP2007535522A (ja) 2007-12-06
AU2011200543A1 (en) 2011-03-03
SG186673A1 (en) 2013-01-30
RU2006142322A (ru) 2008-06-20
BRPI0510500A (pt) 2007-10-30
HUS1300006I1 (hu) 2016-07-28
LU92176I2 (fr) 2013-05-27
EP2422766A2 (en) 2012-02-29
CA2563760A1 (en) 2005-11-10
EP1755555B1 (en) 2012-05-23
CA2563760C (en) 2013-07-02
CY2015059I1 (el) 2020-05-29
AU2005237266B2 (en) 2010-11-11
GB0409703D0 (en) 2004-06-02
IL223545A (en) 2016-04-21
DK1755555T3 (da) 2012-08-20
NO20065502L (no) 2007-01-24
PL2422766T3 (pl) 2015-11-30
JP5124718B2 (ja) 2013-01-23
PL1755555T3 (pl) 2012-11-30
HK1167334A1 (en) 2012-11-30
LTC2422766I2 (lt) 2020-02-10
BRPI0510500B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
SG152292A1 (en) Pharmaceutical compositions
IL185479A0 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
ZA200709691B (en) N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
IL191137A0 (en) Polycation-polyanion complexes, compositions and methods of use thereof
JO2578B1 (en) Compounds Theophene benzimidazole
UA103181C2 (ru) Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент
TW200510344A (en) Aryl-heteroaromatic products, compositions comprising them and use
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TNSN07241A1 (en) Substituted pyrroles, compositions containing same, method for making same and use thereof
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
MXPA05008902A (es) Soluciones de drogas en mentol.
WO2006056695A8 (fr) Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
TW200511987A (en) Topical composition
TW200815363A (en) KV1.5 potassium channel inhibitors
WO2006090265A3 (en) Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
MX2007002814A (es) Geles de testosterona comprendiendo propilenglicol como mejorador de penetracion.
IL183438A0 (en) Substituted indoles, compositions containing them, method for the production thereof and their use
ITMI20040146A1 (it) Ibopamina maleato metodo per prepararlo e composizioni farmaceutiche che lo comprendono
TW200504026A (en) N-aryl-heteroaromatic products, compositions containing them and use thereof
WO2004105738A3 (en) Use of tetrahydropyridine derivatives
WO2006084870A3 (en) Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200744590A (en) Novel compounds
WO2005041875A3 (en) Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications
MY135292A (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors